Skip to content
DataLookout
Menu

NCT07483450

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Primary endpoints: details revised at 1 of 3 entries
    • Secondary endpoints: details revised at 6 of 18 entries
    • Site details revised at 1 of 17 sites
  2. Notable Primary completion pushed from Mar 12, 2027 to Dec 31, 2027
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Study completion pushed from Apr 23, 2027 to Dec 31, 2028
    • Site details revised at 17 of 17 sites
    v4
  3. Minor Site details revised at 1 of 17 sitesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

RMS Cohort: Annualized Protocol-defined Relapse Rate
Timeframe: Up to approximately 1.6 years
PPMS Cohort: B-cell Levels in Blood
Timeframe: Up to Week 48
PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48
Timeframe: At Week 48

Secondary (18)

RMS Cohort: Percentage of Participants Who Have No Evidence of Disease Activity (NEDA3) During a 48-week Period
RMS Cohort: Percentage of Relapse-free Participants by Week 48
RMS Cohort: Percentage of Participants Who Have NEDA3 During a 24-week Period
RMS Cohort: Total Number of T1 Gadolinium (Gd)-enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI)
RMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI
Show 13 moreShow less
RMS and PPMS Cohorts: Change From Baseline to Week 48 in the Concentration of Serum Neurofilament Light Chain (Nfl)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
RMS and PPMS Cohorts: Serum Concentration of Ocrelizumab
RMS Cohort: B-cell Levels in Blood
RMS Cohort: Percentage of Participants Achieving CD19+ B-cell Levels of <10 cells/μL at Week 48
PPMS Cohort: Total Number of T1 Gd-enhancing Lesions as Detected by Brain MRI at Week 24 and Week 48
PPMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI at Week 24 and Week 48
RMS and PPMS Cohorts: Number of Participants With Adverse Events (AEs)
RMS and PPMS Cohorts: Change from Baseline in T-cell Level
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

Arms and interventions

RMS CohortExperimental

Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks).

PPMS CohortExperimental

Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks).

Drugs: Ocrelizumab

Sites

17 sites in 1 country